Cytodyn Inc


Prices are adjusted according to historical splits.

Cytodyn Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$250.94 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Cytodyn Inc had its IPO on under the ticker symbol CYDY.

The company operates in the Healthcare sector and Biotechnology industry. Cytodyn Inc has a staff strength of 23 employees.

Stock update

Shares of Cytodyn Inc opened at $0.21 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.2 - $0.22, and closed at $0.2.

This is a -4.76% slip from the previous day's closing price.

A total volume of 562,828 shares were traded at the close of the day’s session.

In the last one week, shares of Cytodyn Inc have slipped by -9.09%.

Cytodyn Inc's Key Ratios

Cytodyn Inc has a market cap of $250.94 million, indicating a price to book ratio of 1066.0343 and a price to sales ratio of 1174.391.

In the last 12-months Cytodyn Inc’s revenue was $0 with a gross profit of $-73277000 and an EBITDA of $-115555000. The EBITDA ratio measures Cytodyn Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cytodyn Inc’s operating margin was 0% while its return on assets stood at -133.19% with a return of equity of 0%.

In Q0.66666666666667, Cytodyn Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Cytodyn Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.2 per share while it has a forward price to earnings multiple of 10.8108 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cytodyn Inc’s profitability.

Cytodyn Inc stock is trading at a EV to sales ratio of 1274.2234 and a EV to EBITDA ratio of -2.1258. Its price to sales ratio in the trailing 12-months stood at 1174.391.

Cytodyn Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$14.64 million
Total Liabilities
$121.33 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Cytodyn Inc ended 2024 with $14.64 million in total assets and $0 in total liabilities. Its intangible assets were valued at $14.64 million while shareholder equity stood at $-107010000.00.

Cytodyn Inc ended 2024 with $0 in deferred long-term liabilities, $121.33 million in other current liabilities, 837000.00 in common stock, $-823054000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $11.11 million and cash and short-term investments were $11.11 million. The company’s total short-term debt was $36,013,000 while long-term debt stood at $0.

Cytodyn Inc’s total current assets stands at $14.11 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $81.96 million and inventory worth $0.

In 2024, Cytodyn Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Cytodyn Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Cytodyn Inc stock is currently trading at $0.2 per share. It touched a 52-week high of $1.26 and a 52-week low of $1.26. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.23 and 200-day moving average was $0.28 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 600.6% of the company’s stock are held by insiders while 5.5% are held by institutions.

Frequently Asked Questions About Cytodyn Inc

The stock symbol (also called stock or share ticker) of Cytodyn Inc is CYDY

The IPO of Cytodyn Inc took place on

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (“COVID-19”). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.


1111 Main Street, Vancouver, WA, United States, 98660